In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.

Dante’s oncologist, Dr. Bernie Eigl, deputy head, department of clinical research at BC Cancer, referred him to a BC Cancer ...

Dendreon's prostate cancer immunotherapy Provenge has been rejected by NICE in draft guidance, which said its high price and weak evidence based meant it could not be recommended. Provenge ...

White button mushrooms promoted antitumor activity among men with prostate cancer, according to results of an ongoing ...

Lung metastasis (from metastatic breast cancer) resolved - after only 2 months (4 doses) of treatment with Bria-OTS™ ...

In a live event, Vinay Minocha, MD, discusses the addition of darolutamide to androgen deprivation therapy for in patients ...

Androgen deprivation is the mainstay of advanced prostate cancer treatment ... the bone resorption-targeting drug denosumab and an immunotherapy (sipuleucel-T). This article describes the ...

NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced it ...

TUESDAY commemorates World Cancer Awareness Day. This year’s theme is United by Unique which is a patient-centric initiative ...